Prostate Cancer Prevention Clinical Trials – AstraZeneca in Advanced Stages – Part 1

AstraZeneca plc is a huge Anglo-Swedish pharmaceutical business formed on 6 April 1999 by the merger of Swedish Astra AB and British Zeneca Group plc. The organization has been at the forefront of medical study ever given that.

In 2005 AstraZeneca announced an arrangement with Astex for the discovery, development and commercialization of novel modest molecule inhibitors of Protein Kinase B for use as anti-cancer agents. It also announced an alliance with Schering AG for analysis and licensing in the location of selective glucocorticoid receptor agonists. And then only in 2007, they declared that they had been going into phase III trials for their novel drug ZD4054 for patients with a single of the worst types of prostate cancer that there is, hormone resistant or hormone refractory prostate variety of cancer.

The drug – ZD4054 – is an oral agent that has completed promisingly properly in phase II clinical trials. An endothelin a receptor antagonist which blocks cell activity thereby preventing the growth of cancer cells (in some sense) ZD4054 is regarded as to be some form of improvements for hormonal interventions for prostate cancer patients. It operates by certain blockade of the ETA receptor, inhibiting tumor cell proliferation, tumor cell survival, tumor angiogenesis and the pathophysiology of bone metastases in prostate malignant cancer patients.

The concluding component of this write-up will go over far more on the use of this drug in other stages like stage two and the achievement stories or otherwise related with the use of the drug, in the fight against prostate type of cancer.